全文获取类型
收费全文 | 43759篇 |
免费 | 2847篇 |
国内免费 | 251篇 |
专业分类
耳鼻咽喉 | 376篇 |
儿科学 | 1275篇 |
妇产科学 | 1199篇 |
基础医学 | 5790篇 |
口腔科学 | 928篇 |
临床医学 | 4410篇 |
内科学 | 9517篇 |
皮肤病学 | 877篇 |
神经病学 | 4713篇 |
特种医学 | 1481篇 |
外科学 | 5850篇 |
综合类 | 172篇 |
一般理论 | 19篇 |
预防医学 | 3155篇 |
眼科学 | 760篇 |
药学 | 2734篇 |
1篇 | |
中国医学 | 84篇 |
肿瘤学 | 3516篇 |
出版年
2024年 | 10篇 |
2023年 | 472篇 |
2022年 | 387篇 |
2021年 | 1623篇 |
2020年 | 1056篇 |
2019年 | 1484篇 |
2018年 | 1698篇 |
2017年 | 1189篇 |
2016年 | 1339篇 |
2015年 | 1542篇 |
2014年 | 2122篇 |
2013年 | 2642篇 |
2012年 | 3915篇 |
2011年 | 3903篇 |
2010年 | 1972篇 |
2009年 | 1841篇 |
2008年 | 3115篇 |
2007年 | 3002篇 |
2006年 | 2703篇 |
2005年 | 2674篇 |
2004年 | 2231篇 |
2003年 | 1995篇 |
2002年 | 1759篇 |
2001年 | 210篇 |
2000年 | 148篇 |
1999年 | 198篇 |
1998年 | 254篇 |
1997年 | 181篇 |
1996年 | 143篇 |
1995年 | 174篇 |
1994年 | 153篇 |
1993年 | 121篇 |
1992年 | 82篇 |
1991年 | 74篇 |
1990年 | 60篇 |
1989年 | 40篇 |
1988年 | 38篇 |
1987年 | 34篇 |
1986年 | 31篇 |
1985年 | 31篇 |
1984年 | 38篇 |
1983年 | 18篇 |
1982年 | 37篇 |
1981年 | 21篇 |
1980年 | 21篇 |
1979年 | 9篇 |
1978年 | 12篇 |
1977年 | 11篇 |
1976年 | 8篇 |
1972年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 359 毫秒
51.
52.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
53.
54.
55.
Valeria Cento Claudia Alteri Valentina Mancini Milo Gatti Valentina Lepera Ernestina Mazza Maria Cristina Moioli Marco Merli Jacopo Colombo Carlo Andrea Orcese Alessandra Bielli Stefania Torri Laura Elisa Gasparini Chiara Vismara Andrea De Gasperi Paolo Brioschi Massimo Puoti Roberto Cairoli Gianluigi Lombardi Carlo Federico Perno 《Mycoses》2020,63(12):1299-1310
56.
Sarah Hallas Andrea Nelson Susan O'Meara Una Adderley Pauline Meskell Jane Nixon Aonghus O'Loughlin Sebastian Probst Wael Tawfick Thomas Wild Georgina Gethin 《Journal of tissue viability》2021,30(3):317-323
BackgroundA venous leg ulcer is a chronic leg wound caused by poor venous blood circulation in the lower limbs. It is a recurring condition causing pain, malodour, reduced mobility, and depression. Randomised controlled trials evaluating treatments for venous leg ulcers provide important evidence to inform clinical decision-making. However, for findings to be useful, outcomes need to be clinically meaningful, consistently reported across trials, and fully reported. Research has identified the large number of outcomes reported in venous leg ulcer trials, impacting both synthesis of results, and clinical decision-making. To address this, a core outcome set will be developed. A core outcome set is an agreed standardised set of outcomes which should be, as a minimum, measured and reported in all trials which evaluate treatment effectiveness for a given indication. A core outcome set has the potential to reduce research waste, improve the utility of RCTs, reduce reporting bias, facilitate treatment comparisons across different sources of evidence and expedite the production of systematic reviews, meta-analyses and evidence-based clinical guidelines.AimThe aim of this project is to develop a core outcome set for research evaluating the effectiveness of interventions for treating venous leg ulceration.MethodsThrough a scoping review of the literature on venous leg ulceration, we will firstly identify a list of candidate outcome domains (broad categories in relation to what is being measured) from randomised controlled trials and qualitative research, and outcomes (specific methods in relation to what is being measured). In two further stages, we will use the resulting lists of outcome domains and outcomes to design two online surveys. A range of stakeholders will be invited to participate in the surveys and they will be asked to indicate which outcome domains and outcomes are most important and should be considered as core in future research reports. 相似文献
57.
Fabrizio Rao Giancarlo Garuti Michele Vitacca Paolo Banfi Fabrizio Racca Renato Cutrera Martino Pavone Marina Pedemonte Matteo Schisano Stefania Pedroni Jacopo Casiraghi Andrea Vianello Valeria A Sansone UILDM Respiratory group 《Acta myologica》2021,40(1):8
Respiratory complications are common in the patient with muscular dystrophy. The periodic clinical and instrumental respiratory evaluation is extremely important. Despite the presence in the literature of updated guidelines, patient associations often report lack of knowledge of these pathologies, particularly in peripheral hospitals. The purpose of this work, inspired by the Italian Muscular Dystrophy Association (UILDM) is to improve management of respiratory problems necessary for the management of these patients complex. To this end, the main items that the specialist can meet in the follow-up of these pathologies have been analyzed and discussed, among which the respiratory basal evaluation, the criteria of adaptation to non-invasive ventilation, management of bronchial secretions, situations of respiratory emergency, indications for tracheostomy and the subject of advance directives of treatment (DAT).Key words: respiratory failure, muscular dystrophy, cough efficacy, spirometry, polygraphy, non-invasive ventilation, arterial blood gases, cough machine, invasive ventilation, tracheostomy, mechanical ventilation 相似文献
58.
59.
Ivona Markelić Iva Hlapčić Dunja Rogić Ivana Rako Miroslav Samaržija Sanja Popović-Grle Lada Rumora Andrea Vukić Dugac 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(1):153-161
Background and aimsLimited number of studies investigated lipid profile in chronic obstructive pulmonary disease (COPD) with inconsistent results. This study aimed to investigate lipid parameters in sera of patients with stable COPD and their associations with disease severity, smoking, comorbidities and therapy.Methods and resultsThe study included 137 COPD patients and 95 controls. Triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were assessed. Non-HDL-C (NHC), atherogenic coefficient (AC), TG/HDL-C, atherogenic index of plasma (AIP), Castelli's risk index I and II (CRI-I, CRI-II), and monocyte to HDL ratio (MHR) were calculated.HDL-C and MHR were increased, while other lipid parameters and indices were decreased in COPD patients compared to healthy individuals. Smoking did not influence lipid parameters. However, lipid profile was altered only in more severe disease stages. AC, CRI-I and CRI-II showed positive association with lung function parameters in COPD patients, and negative with COPD multicomponent indices (ADO, BODCAT, BODEx, CODEx and DOSE). Combined model that included CRI-II, C-reactive protein, fibrinogen and white blood cells showed great diagnostic performances, and correctly classified 72% of study participants with an AUC of 0.800 (0.742–0.849), P < 0.001. Bronchodilator monotherapy and statins have opposite impact on TC, LDL-C and NHC, while TG, TG/HDL-C and AIP were increased in COPD patients with cardiovascular diseases.ConclusionLipid disbalance is present in COPD, and it seems to occur later as the disease progresses. Further studies are needed to illuminate the underlying mechanism of dyslipidaemia. 相似文献